RU2015125343A - Гуманизированные моноклональные антитела против активированного белка с и их применение - Google Patents
Гуманизированные моноклональные антитела против активированного белка с и их применение Download PDFInfo
- Publication number
- RU2015125343A RU2015125343A RU2015125343A RU2015125343A RU2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- cell
- residue
- cell line
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 101800004937 Protein C Proteins 0.000 claims 3
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 3
- 101800001700 Saposin-D Proteins 0.000 claims 3
- 229960000856 protein c Drugs 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 230000003024 amidolytic effect Effects 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002096 quantum dot Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96461—Protein C (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731368P | 2012-11-29 | 2012-11-29 | |
| US61/731,368 | 2012-11-29 | ||
| PCT/US2013/072137 WO2014085527A1 (en) | 2012-11-29 | 2013-11-27 | Humanized monoclonal antibodies against activated protein c and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015125343A true RU2015125343A (ru) | 2017-01-11 |
Family
ID=50828440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015125343A RU2015125343A (ru) | 2012-11-29 | 2013-11-27 | Гуманизированные моноклональные антитела против активированного белка с и их применение |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9657111B2 (enExample) |
| EP (1) | EP2925360A4 (enExample) |
| JP (1) | JP2016501875A (enExample) |
| KR (1) | KR20150088853A (enExample) |
| CN (1) | CN104936618A (enExample) |
| AR (1) | AR093672A1 (enExample) |
| AU (1) | AU2013352260A1 (enExample) |
| BR (1) | BR112015012458A2 (enExample) |
| CA (1) | CA2892748A1 (enExample) |
| HK (1) | HK1215174A1 (enExample) |
| IL (1) | IL238920A0 (enExample) |
| MX (1) | MX2015006738A (enExample) |
| RU (1) | RU2015125343A (enExample) |
| SG (1) | SG11201504035PA (enExample) |
| TW (1) | TW201437229A (enExample) |
| UY (1) | UY35160A (enExample) |
| WO (1) | WO2014085527A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179435A1 (en) * | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| WO2017087391A1 (en) * | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| US12319744B2 (en) | 2018-09-06 | 2025-06-03 | Board Of Regents, The University Of Texas System | Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR) |
| CN115611986B (zh) * | 2021-07-13 | 2025-08-12 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202253A (en) | 1988-12-30 | 1993-04-13 | Oklahoma Medical Research Foundation | Monoclonal antibody specific for protein C and antibody purification method |
| US7247453B1 (en) | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
| US5279956A (en) * | 1991-06-24 | 1994-01-18 | The Scripps Research Institute | Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C |
| US5695993A (en) | 1994-08-12 | 1997-12-09 | Oklahoma Medical Research Foundation | Cloning and regulation of an endothelial cell protein C/activated protein C receptor |
| DE69735421T2 (de) | 1996-04-24 | 2006-10-19 | The Regents Of The University Of Michigan, Ann Arbor | Gegen inaktivierung resistenter faktor viii |
| US6953568B1 (en) | 1998-08-25 | 2005-10-11 | Oklahoma Medical Research Foundation | Targeting of molecules to large vessel endothelium using EPCR |
| US6989241B2 (en) | 2000-10-02 | 2006-01-24 | Oklahoma Medical Research Foundation | Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor |
| US20030203355A1 (en) | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| TW200407335A (en) * | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| JP4829609B2 (ja) * | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| AU2006330411B2 (en) * | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| US7846443B2 (en) | 2006-08-11 | 2010-12-07 | Schering Corporation | Antibodies to IL-17A |
| US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| WO2009055669A2 (en) * | 2007-10-26 | 2009-04-30 | Oklahoma Medical Research Foundation | Monoclonal antibodies against activated and unactivated protein c |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| GB201011771D0 (en) | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
-
2013
- 2013-11-27 JP JP2015545419A patent/JP2016501875A/ja active Pending
- 2013-11-27 SG SG11201504035PA patent/SG11201504035PA/en unknown
- 2013-11-27 RU RU2015125343A patent/RU2015125343A/ru not_active Application Discontinuation
- 2013-11-27 CA CA2892748A patent/CA2892748A1/en not_active Abandoned
- 2013-11-27 HK HK16103170.8A patent/HK1215174A1/zh unknown
- 2013-11-27 AU AU2013352260A patent/AU2013352260A1/en not_active Abandoned
- 2013-11-27 BR BR112015012458A patent/BR112015012458A2/pt not_active Application Discontinuation
- 2013-11-27 US US14/443,696 patent/US9657111B2/en not_active Ceased
- 2013-11-27 EP EP13857737.4A patent/EP2925360A4/en not_active Ceased
- 2013-11-27 MX MX2015006738A patent/MX2015006738A/es unknown
- 2013-11-27 CN CN201380071700.3A patent/CN104936618A/zh active Pending
- 2013-11-27 KR KR1020157016868A patent/KR20150088853A/ko not_active Withdrawn
- 2013-11-27 WO PCT/US2013/072137 patent/WO2014085527A1/en not_active Ceased
- 2013-11-27 US US16/419,319 patent/USRE49099E1/en active Active
- 2013-11-29 UY UY0001035160A patent/UY35160A/es unknown
- 2013-11-29 TW TW102143763A patent/TW201437229A/zh unknown
- 2013-11-29 AR ARP130104418A patent/AR093672A1/es unknown
-
2015
- 2015-05-20 IL IL238920A patent/IL238920A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015006738A (es) | 2015-08-05 |
| AU2013352260A1 (en) | 2015-06-11 |
| US20150322164A1 (en) | 2015-11-12 |
| AR093672A1 (es) | 2015-06-17 |
| UY35160A (es) | 2014-06-30 |
| SG11201504035PA (en) | 2015-06-29 |
| CA2892748A1 (en) | 2014-06-05 |
| HK1215174A1 (zh) | 2016-08-19 |
| IL238920A0 (en) | 2015-07-30 |
| CN104936618A (zh) | 2015-09-23 |
| KR20150088853A (ko) | 2015-08-03 |
| USRE49099E1 (en) | 2022-06-07 |
| EP2925360A1 (en) | 2015-10-07 |
| WO2014085527A1 (en) | 2014-06-05 |
| BR112015012458A2 (pt) | 2018-02-06 |
| EP2925360A4 (en) | 2016-07-13 |
| TW201437229A (zh) | 2014-10-01 |
| JP2016501875A (ja) | 2016-01-21 |
| US9657111B2 (en) | 2017-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7411029B2 (ja) | 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片 | |
| RU2760875C1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| RU2462475C2 (ru) | Антитела против вируса гепатита с | |
| AU2017237543B2 (en) | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same | |
| CN103864924B (zh) | 一种中东呼吸综合征冠状病毒抗体及其制备方法 | |
| AU2013370009B2 (en) | Anti-granulysin antibodies and methods of use thereof | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| TW200716677A (en) | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| RU2017123549A (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| RU2015125343A (ru) | Гуманизированные моноклональные антитела против активированного белка с и их применение | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| JP2016530223A5 (enExample) | ||
| RU2017145094A (ru) | Нейтрализующие связывающие молекулы, направленные против вируса гриппа, и пути их применения | |
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161128 |